MRK
$142.79+0.60%
as of close, Oct 7, 2026
☾ AH $142.79 +0.60%
Merck & Co. Inc.Stock · HealthcareDow Jones 1.5%S&P 500 0.5%Russell 1000 0.5%US Stock Market 0.4%Russell 3000 0.4%MSCI World 0.3%MSCI ACWI 0.3%S&P 500 Equal Weight 0.2%
MRK — Merck & Co. Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDEDEDEDED
60.070.080.090.0100.0110.0120.0130.0140.0150.00100.0M$142.79—20162019202120242026
2026-10-07
Price$142.79
MA20$130.54
MA50$112.55
Vol33.6M
Key stats#
Price data
- Price
- $142.79
- YTD price return
- +35.65%
- YTD total return
- +38.45%
- Next earnings
- Oct 29, 2026 · Before open
- Market cap
- 352.3B
- Enterprise value
- 400.3B
- Shares outstanding
- 2.5B
- 52W low
- $82.01
- 52W high
- $156.92
- From 52W high
- -9.00%
- From 52W low
- +74.11%
- 52W range
- 81%
- Beta
- 0.19
Volume
- Rel volume
- 0.68×
- 30D volume
- 9.4M
- 30D $ vol
- 1.4B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$30.0M
- Insider net 1Y
- −$70.7M
Form 4 transactions by trade date, as filed; latest on file 2026-08-13.
Fundamentals
- Sales (ttm)
- 66.6B
- Sales/share
- $26.98
- EPS (ttm)
- $1.28
- FCF (ttm)
- 16.1B
- FCF/share
- $6.51
- Book value/share
- $17.00
- Net margin
- 4.77%
- ROE
- 7.57%
- ROA
- 2.44%
- Debt / equity
- 1.22×
- Current ratio
- 1.32
Growth (CAGR, ttm) · 10Y
- Sales
- +4.65%+4.51%+8.68%+5.56%
- Net income
- -80.68%+0.66%-10.65%-4.70%
- FCF
- +9.12%+14.05%+17.76%+4.99%
- Shares
- -1.23%-0.93%-0.51%-1.13%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -80.30%+1.47%-10.23%-3.51%
- Sales/share
- +5.94%+5.50%+9.24%+6.76%
- FCF/share
- +10.47%+15.12%+18.34%+6.20%
- Book value/share
- -13.36%+3.68%+5.26%+0.81%
- Dividend/share
- +5.00%+5.27%+5.59%+6.27%
- Price
- +63.04%+11.17%+11.75%+9.09%
- Total return
- +67.83%+14.61%+15.22%+12.48%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 111.7×
- Fwd P/E
- 15.0×
- P/S (ttm)
- 5.3×
- P/B (mrq)
- 8.4×
- P/FCF (ttm)
- 21.9×
- EV/EBITDA (fy)
- 29.2×
- EV/Sales (ttm)
- 6.0×
- FCF yield (ttm)
- 4.56%
- Dividend yield (fwd)
- 2.38%
- Dividend yield (ttm)
- 2.38%
- Dividend/share (fwd)
- $3.40
- Buyback yield (realized, 1y)
- 1.23%
- Shareholder yield (realized, 1y)
- 5.42%
- Buyback yield (cash, ttm)
- 1.19%
- Shareholder yield (cash, ttm)
- 3.55%
Vs own 10Y history
- P/E
- 91st
- P/S
- 93rd
- P/B
- 97th
- P/FCF
- 45th
Bar = where today’s multiple sits in MRK’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-07#
1D
+0.60%
5D
-1.73%
1M
-5.02%
3M
+10.81%
YTD
+35.65%
1Y
+62.98%
5Y
+74.26%
Recent filings#
- Aug 13Insider sale · Guindo Chirfi (EVP, Access, Policy & Comms) sold 25,000 shares for $3.3M on 2 days since Aug 6
- Aug 12Insider sale · Zachary Jennifer (EVP, General Counsel) sold 80,315 shares for $10.7M at $133.46
- Aug 12Insider sale · DeLuca Richard R. (EVP&Pres, Merck Animal Heallth) sold 51,370 shares for $6.7M on 4 days since Aug 6
- Aug 5Insider sale · Williams David Michael (EVP,Chief Info&Digital Officer) sold 52,847 shares for $6.8M at $128.77
- Aug 5Insider sale · Maraldo David R. (EVP & Pres. MMD) sold 18,706 shares for $2.4M at $128.72
Financial statements
Open full MRK financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +3.42% | +2.70% |
| JNJ | Johnson & Johnson | -6.10% | +1.44% |
| ABBV | AbbVie Inc. | +5.81% | +1.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -5.33% | -0.09% |
| TMO | Thermo Fisher Scientific Inc. | +7.87% | +0.83% |
| AMGN | Amgen Inc. | -5.52% | +2.60% |
| GILD | Gilead Sciences Inc. | -2.75% | +1.82% |
| ABT | Abbott Laboratories | -8.86% | +0.58% |
